TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23890460

Group type: EXPERIMENTAL
Intervention: Aromatherapy massage
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Reflexology
Number of subjects: 115
Study: 20923712

Group type: EXPERIMENTAL
Intervention: Cerebrolysin (10 mL)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Cerebrolysin (30 mL)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 33
Study: 17953718

Group type: EXPERIMENTAL
Intervention: Febuxostat 40 mg
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Febuxostat 80 mg (multiple dosing)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Febuxostat 80 mg (single dosing)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Febuxostat 120 mg (single dosing)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Febuxostat 80 mg (single dosing with antacid)
Number of subjects: 68
Study: 16586149

Group type: EXPERIMENTAL
Intervention: Red wine (0.35 mg hydroxytyrosol)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Olive oil (1.7 mg hydroxytyrosol)
Number of subjects: 0
Study: 14613272

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg/day
Number of subjects: 475

Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg/day
Number of subjects: 475

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 475
Study: 10743881

Group type: EXPERIMENTAL
Intervention: High levels of power motivation and strong power-sex associations in men
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High levels of affiliation-intimacy motivation in women
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Strong power-sex associations in women with high affiliation-intimacy motivation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Weak power-sex associations in men
Number of subjects: 0
Study: 8697551

Group type: EXPERIMENTAL
Intervention: TOF-DI
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PTT-DI
Number of subjects: 60
Study: 1396254

Group type: EXPERIMENTAL
Intervention: Indomethacin therapy
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Surgical closure of the ductus arteriosus
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Indomethacin therapy (presymptomatic treatment)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Ductus arteriosus size at 3 days (ultrasound study)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Moderate to large ductus arteriosus at 3 days
Number of subjects: 110
Study: 3906673

Group type: EXPERIMENTAL
Intervention: Baclofen (25 to 60 mg per day)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Diazepam (10 to 40 mg per day)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Baclofen (long-term study)
Number of subjects: 13
Study: 30710885

Group type: EXPERIMENTAL
Intervention: ω-3 supplementation
Number of subjects: 68

Group type: COMPARATOR
Intervention: Standard formula without ω-3 (control group)
Number of subjects: 68
Study: 29351167

Group type: EXPERIMENTAL
Intervention: Caffeine intake
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 27442674

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 μg/kg loading before anesthesia induction and 0.3 μg/kg/h infusion during surgery)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 60
Study: 24637890

Group type: EXPERIMENTAL
Intervention: Early surgery
Number of subjects: 379

Group type: COMPARATOR
Intervention: Prolonged conservative care
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Disabling back pain
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Disabling back pain without nerve root compression
Number of subjects: 379
Study: 22240172

Group type: EXPERIMENTAL
Intervention: 1-day mifepristone-misoprostol interval
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: 2-day mifepristone-misoprostol interval
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: History of curettage
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Fetal indications for TOP
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Age above 24 years
Number of subjects: 227
Study: 21069596

Group type: EXPERIMENTAL
Intervention: Music therapy (MT) treatment with three cycles of 12 active sessions each, three times a week for one month, followed by one month of no treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard care (educational and entertainment activities)
Number of subjects: 60
Study: 17706003

Group type: EXPERIMENTAL
Intervention: Aripiprazole (starting dose 15 mg/day, adjusted 10-30 mg/day)
Number of subjects: 833

Group type: COMPARATOR
Intervention: Safety Control (another antipsychotic)
Number of subjects: 833
Study: 16115174

Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Latanoprost
Number of subjects: 0
Study: 12391438

Group type: EXPERIMENTAL
Intervention: PL-irradiation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (no-irradiation)
Number of subjects: 30
Study: 9563219

Group type: EXPERIMENTAL
Intervention: Propranolol (60 mg twice daily for seven days)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 8129128

Group type: EXPERIMENTAL
Intervention: Alfentanil 0.2 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Morphine 5 mg
Number of subjects: 20
Study: 2799742

Group type: COMPARATOR
Intervention: Simple drainage
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Tetracycline pleurodesis
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Talc pleurodesis
Number of subjects: 96
Study: 30305278

Group type: EXPERIMENTAL
Intervention: Stand More AT (SMArT) Work intervention
Number of subjects: 146

Group type: COMPARATOR
Intervention: Control group (usual practice)
Number of subjects: 146
Study: 28625382

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Nocturnal Supplemental Oxygen (NSO)
Number of subjects: 318

Group type: COMPARATOR
Intervention: Healthy Lifestyle Education (HLSE)
Number of subjects: 318
Study: 26637222

Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric care (CGC)
Number of subjects: 397

Group type: COMPARATOR
Intervention: Orthopedic care (OC)
Number of subjects: 397
Study: 23760221

Group type: EXPERIMENTAL
Intervention: Posthorax support vest®
Number of subjects: 2539

Group type: COMPARATOR
Intervention: No vest (control group)
Number of subjects: 2539
Study: 20592387

Group type: EXPERIMENTAL
Intervention: 500 microg sodium selenite on days of radiotherapy and 300 microg sodium selenite on days without radiotherapy (Group A)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (Group B) received irradiation without any selenium substitution
Number of subjects: 39
Study: 18054848

Group type: EXPERIMENTAL
Intervention: Polyunsaturated fatty acid 2g/day
Number of subjects: 40

Group type: COMPARATOR
Intervention: AHA regular diet
Number of subjects: 40
Study: 15864241

Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 1205

Group type: COMPARATOR
Intervention: PCI
Number of subjects: 1205

Group type: COMPARATOR
Intervention: CKD (compared to normal renal function)
Number of subjects: 1205
Study: 12930014

Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide vaginal douching (20 ml of 3% hydrogen peroxide)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Oral metronidazole (2 grams)
Number of subjects: 142
Study: 10639383

Group type: EXPERIMENTAL
Intervention: Intravenous ceftriaxone (CRO) for 7 days (short course; n = 29)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Intravenous ceftriaxone (CRO) for 14 days (conventional; n = 28)
Number of subjects: 57
Study: 8846276

Group type: EXPERIMENTAL
Intervention: 25 G Quincke needle
Number of subjects: 60

Group type: COMPARATOR
Intervention: 29 G Quincke needle
Number of subjects: 60
Study: 1803175

Group type: EXPERIMENTAL
Intervention: Modified radical mastectomy
Number of subjects: 263

Group type: COMPARATOR
Intervention: Radical mastectomy
Number of subjects: 263
Study: 6840163

Group type: EXPERIMENTAL
Intervention: Isosorbide-dinitrate (ISDN) 20 mg 4 times daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Isosorbide-dinitrate (ISDN)
Number of subjects: 12
Study: 30921171

Group type: EXPERIMENTAL
Intervention: Digital storytelling and routine training
Number of subjects: 80

Group type: COMPARATOR
Intervention: Routine training (Control)
Number of subjects: 80
Study: 28427595

Group type: EXPERIMENTAL
Intervention: Intracoronary nitroglycerine (NTG) 200 μg
Number of subjects: 0
Study: 26482786

Group type: EXPERIMENTAL
Intervention: Antismoking advertisements (various themes including anti-industry, health effects+anti-industry, sexual health, secondhand smoke, environment+anti-industry)
Number of subjects: 782

Group type: COMPARATOR
Intervention: Control group (no antismoking advertisements)
Number of subjects: 782
Study: 25221387

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/day
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 22902808

Group type: EXPERIMENTAL
Intervention: Cell-free DNA levels decrease in patients with severe TBI
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Cell-free DNA levels decrease in survivors from 0 to 24 hours
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Cut-off point for cf-DNA ratio
Number of subjects: 65
Study: 19615062

Group type: EXPERIMENTAL
Intervention: BioGlue
Number of subjects: 10

Group type: COMPARATOR
Intervention: Peri-strips
Number of subjects: 10
Study: 16650261

Group type: EXPERIMENTAL
Intervention: Inhaled nitrous oxide (50% N2O/50% O2)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Nalbuphine infusion (20 mg over 15 minutes)
Number of subjects: 76
Study: 14711185

Group type: EXPERIMENTAL
Intervention: Enoxaparin plus tirofiban
Number of subjects: 68

Group type: COMPARATOR
Intervention: Nadroparin plus tirofiban
Number of subjects: 68
Study: 10947750

Group type: EXPERIMENTAL
Intervention: Remifentanil (0.25 microg x kg(‐1) x min(‐1))
Number of subjects: 271

Group type: COMPARATOR
Intervention: Epidural bupivacaine
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 271
Study: 8828672

Group type: EXPERIMENTAL
Intervention: Autologous erythrocyte infusion (700-ml infusion, 42% hematocrit)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (saline only)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Erythrocyte infusion
Number of subjects: 16
Study: 1385599

Group type: EXPERIMENTAL
Intervention: Hamilton Depression Scale (HAM-D) items analyzed using Smallest Space Analysis (SSA-I)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Facet 'centrality'
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New combination and selection of items reflecting different facets of depression
Number of subjects: 0
Study: 6317162

Group type: EXPERIMENTAL
Intervention: Hyperalimentation
Number of subjects: 80

Group type: COMPARATOR
Intervention: No parenteral nutrition
Number of subjects: 80
Study: 31074816

Group type: EXPERIMENTAL
Intervention: Vitamin B6 intake ≥35 mg/d
Number of subjects: 75864

Group type: EXPERIMENTAL
Intervention: Vitamin B12 intake ≥30 μg/d
Number of subjects: 75864

Group type: EXPERIMENTAL
Intervention: Combined high intake of both vitamins (B6 ≥35 mg/d and B12 ≥20 μg/d)
Number of subjects: 75864
Study: 27203452

Group type: EXPERIMENTAL
Intervention: Two-stage teaching technique (n=72)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Four-stage teaching technique (n=70)
Number of subjects: 142
Study: 27487638

Group type: EXPERIMENTAL
Intervention: Ketorolac 0.5 mg/kg
Number of subjects: 66

Group type: COMPARATOR
Intervention: Pethidine 1 mg/kg
Number of subjects: 66
Study: 24350872

Group type: EXPERIMENTAL
Intervention: Intensive anti-hypertensive therapy with a systolic target of <140 mmHg within one hour
Number of subjects: 2839

Group type: COMPARATOR
Intervention: Standard guideline recommended treatment of <180 mmHg
Number of subjects: 2839

Group type: EXPERIMENTAL
Intervention: Intensive anti-hypertensive therapy
Number of subjects: 2839

Group type: COMPARATOR
Intervention: Both groups (Intensive and Standard treatment)
Number of subjects: 2839
Study: 22496198

Group type: EXPERIMENTAL
Intervention: IFNβ‐1b 250 μg
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: IFNβ‐1b 50 μg
Number of subjects: 372

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 372
Study: 19346966

Group type: EXPERIMENTAL
Intervention: Atazanavir (400 mg once daily) - immediate switch
Number of subjects: 246

Group type: COMPARATOR
Intervention: Atazanavir (400 mg once daily) - delayed switch
Number of subjects: 246
Study: 17459076

Group type: EXPERIMENTAL
Intervention: Daclizumab
Number of subjects: 39

Group type: COMPARATOR
Intervention: Anti-thymocyte globulin (ATG)
Number of subjects: 39
Study: 15927285

Group type: EXPERIMENTAL
Intervention: Early abciximab administration (27 patients)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Late abciximab administration (28 patients)
Number of subjects: 55
Study: 14509516

Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Concurrent and adjuvant chemotherapy
Number of subjects: 0
Study: 10824633

Group type: EXPERIMENTAL
Intervention: Flumazenil (0.4 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Physostigmine (0.5 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (physiologic saline solution)
Number of subjects: 12
Study: 8865766

Group type: EXPERIMENTAL
Intervention: Prepractice
Number of subjects: 0

Group type: COMPARATOR
Intervention: No prepractice (Control)
Number of subjects: 0
Study: 1615141

Group type: EXPERIMENTAL
Intervention: Scopolamine hydrobromide, 0.43 mg/70 kg, administered by subcutaneous injection
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 6425892

Group type: EXPERIMENTAL
Intervention: Scopolamine 1.2 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nicotine 0.5 mg, 1.0 mg, and 1.5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (in the second experiment)
Number of subjects: 0
Study: 30312183

Group type: EXPERIMENTAL
Intervention: Oral midodrine for 30 days
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Oral midodrine for 2 days
Number of subjects: 75

Group type: COMPARATOR
Intervention: Albumin infusion
Number of subjects: 75
Study: 30234623

Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A (BTX‐A) injection into the gastrocnemius‐soleus muscle at the time of hindfoot stall
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo injection into the gastrocnemius‐soleus muscle at the time of hindfoot stall
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Rescue BTX‐A injection at 12 weeks after the first injection (T2)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Overall manipulation and cast protocol (with or without BTX‐A)
Number of subjects: 62
Study: 27107601

Group type: EXPERIMENTAL
Intervention: Telfa nasal packs in sutures + telfa group (n=22)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Merocell nasal packs in merocel alone group (n=22)
Number of subjects: 66

Group type: COMPARATOR
Intervention: No packs in sutures alone group (n=22)
Number of subjects: 66
Study: 23800984

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine (1 μg/kg)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Intranasal ketamine (5 mg/kg)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine and ketamine
Number of subjects: 150
Study: 21858591

Group type: EXPERIMENTAL
Intervention: Web-based survey
Number of subjects: 6000

Group type: EXPERIMENTAL
Intervention: Mail survey
Number of subjects: 6000

Group type: COMPARATOR
Intervention: Postal mail survey
Number of subjects: 6000
Study: 20229022

Group type: COMPARATOR
Intervention: Continuous exercise (CONT)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Interval exercise (INT)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Acute cold exposure (ACE)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Post-exercise recovery (REC)
Number of subjects: 14
Study: 18833106

Group type: EXPERIMENTAL
Intervention: Torin (generic sertraline)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Zoloft (original sertraline)
Number of subjects: 40
Study: 16225510

Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 11980557

Group type: EXPERIMENTAL
Intervention: Ritonavir-containing antiretroviral therapy
Number of subjects: 197
Study: 10073742

Group type: EXPERIMENTAL
Intervention: 0.4 mg tamsulosin
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 5 mg terazosin
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 7718461

Group type: EXPERIMENTAL
Intervention: Cryotherapy at 1-week intervals
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Cryotherapy at 2-week intervals
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Cryotherapy at 3-week intervals
Number of subjects: 225
Study: 1904163

Group type: EXPERIMENTAL
Intervention: Misoprostol 200 micrograms morning and evening
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 7027431

Group type: EXPERIMENTAL
Intervention: Bromhexine (Bisolvon) 48 mg daily for 3 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 29668401

Group type: EXPERIMENTAL
Intervention: Constraint-Induced Movement Therapy (CIMT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Complementary and Alternative Medicine (CAM)
Number of subjects: 20
Study: 28719012

Group type: EXPERIMENTAL
Intervention: ART plus 5 days of IVIG
Number of subjects: 10

Group type: COMPARATOR
Intervention: ART alone
Number of subjects: 10
Study: 25482574

Group type: COMPARATOR
Intervention: Schizophrenia patients
Number of subjects: 32

Group type: COMPARATOR
Intervention: Schizotypal personality disorder (SPD) patients
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Healthy controls (HCs)
Number of subjects: 32
Study: 23582638

Group type: EXPERIMENTAL
Intervention: Recombinant adenovirus HIV1 vaccine
Number of subjects: 777
Study: 21378591

Group type: EXPERIMENTAL
Intervention: Soft toric contact lenses (2 toric lenses in phase 1, 4 toric lenses in phase 2)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Soft toric contact lenses (4 toric lenses in phase 2)
Number of subjects: 45
Study: 19142413

Group type: EXPERIMENTAL
Intervention: Aripiprazole (mean dose 9.6 mg/day)
Number of subjects: 32
Study: 16644602

Group type: EXPERIMENTAL
Intervention: Atovaquone plus cholestyramine
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo plus cholestyramine
Number of subjects: 25
Study: 12970729

Group type: EXPERIMENTAL
Intervention: 10 ml of 1% lignocaine in the periprostatic tissue prior to biopsy
Number of subjects: 64

Group type: COMPARATOR
Intervention: Standard biopsy
Number of subjects: 64
Study: 11194411

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 34

Group type: COMPARATOR
Intervention: Men
Number of subjects: 34
Study: 8672415

Group type: EXPERIMENTAL
Intervention: Cholecalciferol 10 or 20 micrograms/d for 4, 5 and 9 weeks
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Cholecalciferol administration
Number of subjects: 3
Study: 1596003

Group type: EXPERIMENTAL
Intervention: Oral sustained-release theophylline (Theodur)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 6140978

Group type: EXPERIMENTAL
Intervention: Triprolidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Terfenadine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31391387

Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 254

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 254
Study: 29540227

Group type: COMPARATOR
Intervention: Healthy eating and physical activity promotion intervention (HE + PA intervention)
Number of subjects: 435

Group type: COMPARATOR
Intervention: Healthy eating promotion intervention (HE intervention)
Number of subjects: 435

Group type: COMPARATOR
Intervention: Physical activity promotion intervention (PA intervention)
Number of subjects: 435

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 435
Study: 27184759

Group type: EXPERIMENTAL
Intervention: 3000µg/month oral vitamin D3 by the mother (group A)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: 10µg/d by the infant (group B)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Double placebo (group C)
Number of subjects: 230
Study: 24149079

Group type: EXPERIMENTAL
Intervention: AS03(B)-adjuvanted vaccine
Number of subjects: 274

Group type: COMPARATOR
Intervention: Nonadjuvanted vaccine
Number of subjects: 274
Study: 23788090

Group type: EXPERIMENTAL
Intervention: Normal body mass patients with moderate knowledge about the disease
Number of subjects: 1986

Group type: EXPERIMENTAL
Intervention: Normal body mass patients with full knowledge of health indicators
Number of subjects: 1986

Group type: EXPERIMENTAL
Intervention: Normal body mass patients with supportive family environment
Number of subjects: 1986

Group type: EXPERIMENTAL
Intervention: Normal body mass patients with favourable socio-living situation
Number of subjects: 1986

Group type: EXPERIMENTAL
Intervention: Normal body mass patients requiring less professional care
Number of subjects: 1986

Group type: EXPERIMENTAL
Intervention: Normal body mass patients with normal blood pressure
Number of subjects: 1986

Group type: EXPERIMENTAL
Intervention: Normal body mass patients with normal triglyceride concentrations
Number of subjects: 1986

Group type: EXPERIMENTAL
Intervention: Normal body mass patients with normal total cholesterol concentrations
Number of subjects: 1986

Group type: EXPERIMENTAL
Intervention: Patients with obesity and no physical activity
Number of subjects: 1986

Group type: EXPERIMENTAL
Intervention: Patients with obesity and excessive physical activity
Number of subjects: 1986
Study: 21793317

Group type: EXPERIMENTAL
Intervention: Eleutherococcus senticosus (ES) 800 mg/d
Number of subjects: 9
Study: 18834621

Group type: EXPERIMENTAL
Intervention: p53 overexpression in GOG-157 cohort (paclitaxel+carboplatin)
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: p53 overexpression in GOG-111 cohort (cyclophosphamide+cisplatin vs. paclitaxel+cisplatin)
Number of subjects: 279
Study: 16634838

Group type: EXPERIMENTAL
Intervention: Cinnamon extract (3 g of cinnamon powder per day)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo capsule
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Cinnamon extract
Number of subjects: 79